Skip to main content

Hybrid drug-loaded plasmonic photothermal microneedle patch against skin infections

Objective

In this proof of concept project, we will assess the technical and commercial feasibility of a hybrid microneedle patch for the treatment of nosocomial skin infections caused by drug resistant bacteria. Not only does this device permeate difficult-to-penetrate skin layers to deliver antibiotics locally, it also weakens bacterial defences by raising local temperature to enhance drug effectiveness. In this manner, the need for high dosage systemic drug administration is avoided – reducing occurrence of associated side-effects and perpetuation of antimicrobial resistance. It holds the potential not only to revitalise antibacterials for topical, local treatment of skin infections, but to improve dermatological drug delivery as a platform device. In this project, we will validate the device’s fabrication process for additional commercial scalability and functionality with nanocarrier-drug complexes (for enhanced effectiveness of drug delivery to target site), develop a robust IP strategy and secure initial patents, and conduct extensive market analyses and competitor landscaping. Finally, we will formulate a strong business case, and depending on the results of these activities, establish a company.

Call for proposal

ERC-2020-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

KAROLINSKA INSTITUTET
Address
Nobels Vag 5
17177 Stockholm
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 100 000

Beneficiaries (2)

KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 100 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
KAROLINSKA INSTITUTET HOLDING AB
Sweden
EU contribution
€ 50 000
Address
Nanna Svartz Väg 6 A
171 65 Solna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)